Though lower ANA titers and antiphospholipid antibody positivity have been extensively reported in MS and MS-like populations (Spadaro et al., 1999; Szmyrka-Kaczmarek et al., 2012; Malyavantham et al., 2015; Merashli et al., 2017), in the current report, we emphasize the role of higher ANA titers (more than 1/320) pointing toward an underlying systemic autoimmune process, in support of previous findings (Magro Checa et al., 2013). The gene discussed is BTG3; the disease is myeloid sarcoma.